NHS Central and South Genomics
NHS-administered regional genomics service based in Birmingham providing genomic testing, genetic diagnostics, precision medicine, and hereditary disease screening to NHS hospitals, clinics, and patients across central and south England.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingServices
What NHS Central and South Genomics does
NHS Central and South Genomics is a publicly administered regional genomics service operating under NHS England, headquartered in Birmingham, United Kingdom. The entity delivers genomic testing, genetic diagnostics, precision medicine, and hereditary disease screening to NHS hospitals, clinics, and patients across the central and south England footprint. Operationally it is a regional hub of the NHS Genomic Medicine Service, with referral pathways integrated into NHS clinical workflows.
The service mix covers hereditary and rare-disease testing as well as cancer-relevant genomic diagnostics, positioning the entity within statutory population-level genomic screening mandates rather than consumer or research genomics. With a disclosed headcount of approximately seven employees, the unit appears to function as a coordinating or hub-and-spoke administrative structure rather than a standalone high-throughput sequencing laboratory; detailed laboratory operating model, throughput, and capacity data are not disclosed in the input.
The business model is public-sector commissioning rather than commercial revenue. Funding flows via NHS England block-commissioned allocations for genomic medicine services, with no disclosed fee-for-service pricing, payor mix, or contract values. There are no funding rounds, M&A activity, partnerships, leadership changes, or product launches documented in the available data, consistent with a publicly administered service unit operating under a fixed regional mandate.
NHS Central and South Genomics firmographics
Firmographics- Name
- NHS Central and South Genomics
- Legal name
- NHS Central and South Genomics
- Website
- https://centralsouthgenomics.nhs.uk
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NHS-administered regional genomics service based in Birmingham providing genomic testing, genetic diagnostics, precision medicine, and hereditary disease screening to NHS hospitals, clinics, and patients across central and south England.
- Ownership category
- akta.pro rank
NHS Central and South Genomics industry classification
Industry- Product category
- Clinical Genomics Services
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)
Keywords
NHS Central and South Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
NHS Central and South Genomics product offering
Product offeringCore offering
NHS Central and South Genomics delivers genomic testing and diagnostic services to NHS hospitals, clinics, and patients across central and south England. Its core work spans hereditary disease screening, rare disease diagnostics, and cancer genomic testing, supporting clinical decision-making and personalised medicine pathways within the publicly funded UK health system.
Differentiator
Problem solved
Functional benefit
Products and services
- Genomic testing services Comprehensive genomic testing delivered to NHS hospitals, clinics, and patients across central and south England to support clinical diagnostics and personalised medicine pathways.
- Hereditary disease screening Genetic diagnostics and screening for hereditary conditions, supporting NHS clinicians in identifying inherited disease risk and informing clinical decision-making.
- Rare disease genetic diagnostics Genomic diagnostic services targeted at rare disease identification for NHS patients, enabling diagnosis of genetic disorders across the central and south England population.
- Cancer genomic testing Cancer-focused genomic testing that supports personalised treatment decisions and precision medicine pathways for NHS patients with cancer.
Companies that use NHS Central and South Genomics
Customer profileSegments1 record
Ideal customer profiles2 records
NHS Central and South Genomics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NHS Central and South Genomics partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights2 records
NHS Central and South Genomics competitors and assessment
Company assessmentBroad incumbents
- Invitae: US-based clinical genetics testing company offering hereditary disease, reproductive health, and oncology genetic testing. Comparable as a commercial clinical genomics provider competing for the same broad hereditary and rare disease diagnostic use cases, though operating outside the UK NHS.
- Sonic Healthcare UK: International clinical diagnostics provider with UK pathology and laboratory operations including genetic testing services. Comparable as a clinical laboratory services provider delivering genetic and molecular diagnostics to UK healthcare providers, including NHS contracts.
- Genomics England: UK-government-backed organisation running the 100,000 Genomes Project and operating as the national umbrella coordinating NHS genomic medicine services. Directly comparable as a publicly funded UK genomics entity operating alongside NHS regional providers like NHS Central and South Genomics.
- Illumina: Global leader in next-generation sequencing platforms and reagents widely used in clinical genomics laboratories. Comparable as the dominant upstream technology provider whose sequencing instruments underpin NHS regional labs' molecular and genetic testing workflows.
Direct peers
- NHS North Thames Genomic Medicine Service: One of the NHS England regional Genomic Medicine Service alliances providing clinical genomic testing for a defined UK catchment. Comparable as a peer regional NHS genomics service delivering hereditary, rare disease, and cancer testing under the same national NHS framework.
- NHS North East and Yorkshire Genomic Medicine Service: NHS England regional Genomic Medicine Service covering the North East and Yorkshire region. Directly comparable as a sister NHS regional genomics provider delivering the same clinical testing portfolio across a different UK catchment.
- NHS South East Genomic Medicine Service: NHS England regional Genomic Medicine Service covering the South East of England. Comparable as a peer NHS regional genomics service delivering hereditary, rare disease, and cancer diagnostics under the NHS commissioning framework.
Regional players
- CENTOGENE: Germany-headquartered clinical genomics and rare disease diagnostics company with European market presence. Comparable as a clinical genomics provider focused on rare disease and hereditary diagnostics, overlapping with NHS Central and South Genomics' rare disease mandate but operating primarily in continental Europe.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
NHS Central and South Genomics social profiles
Digital presenceNHS Central and South Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NHS Central and South Genomics leadership team
Management profileNumber of profiles
NHS Central and South Genomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NHS Central and South Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NHS Central and South Genomics
What does NHS Central and South Genomics do?
NHS Central and South Genomics delivers genomic testing and diagnostic services to NHS hospitals, clinics, and patients across central and south England. Its core work spans hereditary disease screening, rare disease diagnostics, and cancer genomic testing, supporting clinical decision-making and personalised medicine pathways within the publicly funded UK health system.
Is NHS Central and South Genomics a public or private company?
NHS Central and South Genomics is a private company. It is classified as state government owned and is currently operating.
When was NHS Central and South Genomics founded?
NHS Central and South Genomics was founded in -1. It employs 1 to 10 people.
Who are NHS Central and South Genomics's main competitors?
Broad incumbents on record are Invitae, Sonic Healthcare UK, Genomics England and Illumina. Direct peers are NHS North Thames Genomic Medicine Service, NHS North East and Yorkshire Genomic Medicine Service and NHS South East Genomic Medicine Service. CENTOGENE is listed as a regional player.
Does NHS Central and South Genomics have an API?
No public API is recorded for NHS Central and South Genomics.
What industry is NHS Central and South Genomics in?
NHS Central and South Genomics's product category is Clinical Genomics Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 621511 and its SIC code is 8071.